GLP1R and diabetic kidney disease: Renin-Angiotensin-Aldosterone System (RAAS) Modulation: Activation of the intrarenal RAAS is a known pathogenic mediator of DKD, and there is evidence that GLP-1R agonists can reduce markers of renal RAAS activation, including angiotensin II levels and its deleterious effects in the glomerulus [27].